To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Fundamental basic laboratory, clinical, and population research are the foundation for all of Karmanos Cancer Institute's Research Programs, which are ultimately directed toward the prevention, early detection or treatment of cancer.
Our Programs include: Tumor Biology and Microenvironment (TBM), Molecular Imaging (MI), Molecular Therapeutics (MT) and Population Studies and Disparities Research (PSDR).
The cancer focus is comprehensive, and encompasses etiology, epidemiology, and prevention, early detection (particularly focused on minority populations), basic and translational research, clinical care (based upon multidisciplinary teams) and clinical research (including investigator-initiated and cooperative group clinical trials).
More than 67 thousand Americans will learn they have head or neck cancer this year, according to the American Cancer Society’s latest estimates .&...
Detroit PBS Hayley Thompson, Ph.D., associate center director of Community Outreach and Education, and faculty supervisor of the Office of C...
Two of Detroit’s biggest Lions fans, mother and daughter breast cancer survivors Brenda Rushlow and Pamela Haddox, have been chosen by the America...